Henrotin, Y. http://orcid.org/0000-0002-2846-4398
Malaise, M.
Wittoek, R.
de Vlam, K.
Brasseur, J.-P.
Luyten, F. P.
Jiangang, Q.
Van den Berghe, M.
Uhoda, R.
Bentin, J.
De Vroey, T.
Erpicum, L.
Donneau, A. F.
Dierckxsens, Y.
Article History
Received: 15 November 2018
Accepted: 17 July 2019
First Online: 27 July 2019
Ethics approval and consent to participate
: The study protocol was approved by the Central Ethics Committee of the University Hospital of Liège in Belgium (namely Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège), agreement number: 707. This RCT was also registered on Clinical ExternalRef removed on 13 September 2016 (NCT02909621).
: Not applicable
: YH is a consultant for Tilman SA and the founder and chairman of Artialis SA, a spin-off company of the University of Liège developing biomarkers. Artialis SA is the manufacturer of coll2-1 immunoassay. YD is an employee of Tilman SA. All other authors declare that they have no competing interests.